* Vivos Therapeutics Inc is expected to show a fall in quarterly revenue when it reports results on March 28 (estimated) for the period ending December 31 2023
* The Littleton Colorado-based company is expected to report a 13.8% decrease in revenue to $3.406 million from $3.95 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Vivos Therapeutics Inc is for a loss of $1.90 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Vivos Therapeutics Inc is $7.13, above its last closing price of $4.55.
This summary was machine generated March 26 at 11:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments